PE-22-28
Research Peptide | Lyophilized Powder | Batch Tested
For laboratory research use only. Not for human or animal consumption. Insulated shipping · Styrofoam box available.
Product Overview
PE-22-28 is a synthetic peptide derived from spadin, an endogenous fragment of the sortilin propeptide. It selectively blocks the TREK-1 potassium channel and is studied as a fast-acting antidepressant research candidate.
| Test | Result | Status |
|---|---|---|
| Purity | 98.9% | Passed ✓ |
| Test | Result | Status |
|---|---|---|
| Purity | 98.6% | Passed ✓ |
Research Information
PE-22-28 is investigated for TREK-1 channel inhibition and the downstream effects on serotonergic signaling, neurogenesis and synaptic plasticity in animal and cell models of depression, where TREK-1 blockade is associated with rapid antidepressant-like responses. Supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption.
PE-22-28 Research & Studies
What is PE-22-28?
PE-22-28 is a synthetic peptide analog derived from spadin, an endogenous fragment of the sortilin propeptide. It is characterized by its ability to selectively interact with the TREK-1 potassium channel. In laboratory settings, PE-22-28 is examined as a research tool for probing TREK-1 function and related signaling cascades. Material is supplied strictly for in-vitro and controlled laboratory research use only.
Mechanism of Action
PE-22-28 is studied for selective blockade of the TREK-1 (KCNK2) two-pore-domain potassium channel. Channel inhibition is investigated for its influence on neuronal excitability and downstream modulation of serotonergic pathways. Research models explore how TREK-1 blockade may alter membrane potential dynamics and second-messenger systems linked to synaptic plasticity. These mechanistic studies are conducted in cellular and tissue preparations under controlled experimental conditions.
Primary Areas of Research
Investigations of PE-22-28 focus on TREK-1 channel inhibition and associated effects on serotonergic signaling. Additional research areas include neurogenesis markers and indicators of synaptic plasticity within cell-based and animal models of depressive-like phenotypes. Scientists use the peptide to examine rapid-onset molecular responses following TREK-1 blockade. All work remains confined to non-clinical laboratory systems.
Key Research Findings
Laboratory studies report that PE-22-28 produces TREK-1 inhibition consistent with rapid antidepressant-like behavioral readouts in validated animal models. Parallel cell-culture work has documented changes in signaling pathways related to neuronal survival and plasticity after channel blockade. Findings are limited to preclinical experimental systems and do not extend to clinical interpretation. Results continue to inform structure-activity relationships among spadin-derived peptides.
Research Handling & Considerations
PE-22-28 is intended solely for qualified laboratory personnel conducting in-vitro or approved animal-model research. Standard peptide-handling practices apply, including appropriate storage, reconstitution, and documentation of experimental conditions. Researchers should verify purity and concentration for each lot prior to use. The compound is not for human or animal consumption and carries no approved therapeutic designation.
Frequently Asked Questions
PE-22-28 is studied for selective inhibition of the TREK-1 (KCNK2) potassium channel in cellular and tissue models.
Explore Other High-Purity Peptides
Epithalon
DSIP
Selank
